Skip to main content
Wockhardt Ltd logo

Wockhardt Ltd — Investor Relations & Filings

Ticker · WOCKPHARMA ISIN · INE049B01025 LEI · 3358001OC2OX7OZAHZ33 BSE.NS Manufacturing
Open in API
Filings indexed 861 across all filing types
Latest filing 2025-07-17 Regulatory Filings
Country IN India
Listing BSE.NS WOCKPHARMA

About Wockhardt Ltd

https://www.wockhardt.com/

Wockhardt Ltd is a research-driven global organization focused on the development and manufacturing of formulations, biopharmaceuticals, and active pharmaceutical ingredients (APIs). The company maintains a specialized focus on drug discovery, particularly in the field of anti-infectives and New Chemical Entities (NCEs) aimed at addressing antimicrobial resistance. Its therapeutic portfolio encompasses diverse areas such as diabetes, nephrology, cardiology, and respiratory health. With a strong emphasis on research and development, the company operates multiple manufacturing facilities that comply with international regulatory standards. Wockhardt provides medical solutions across various international markets, utilizing its expertise in complex chemistry and biotechnology to address unmet clinical needs.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming compliance related to dematerialisation of securities for the quarter ended 30th June 2025. It is a compliance certificate from the Registrar and Share Transfer Agent to the company and stock exchanges. The document is short (3203 characters) and primarily serves as a regulatory compliance confirmation rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed financial data. It is not an announcement of a report but a certificate confirming regulatory compliance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance certificates and regulatory confirmations.
2025-07-17 English
Record Date
AGM Information Classification · 95% confidence The document is a formal communication from Wockhardt Limited to stock exchanges regarding the record date for the 26th Annual General Meeting (AGM). It specifies the date for eligibility to attend and vote at the AGM but does not contain any AGM materials, presentations, or detailed reports. The document is short (1401 characters) and serves as an announcement related to the AGM event, specifically about the record date for voting rights. This fits the category of AGM Information (AGM-R), which includes materials and notices related to the AGM, such as record dates and meeting logistics.
2025-07-16 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is a notice dated July 16, 2025, from Wockhardt Limited addressed to stock exchanges regarding the 26th Annual General Meeting (AGM) scheduled for August 8, 2025. It includes the Notice of the AGM and the Annual Report for the financial year 2024-25. The content includes agenda items such as adoption of audited financial statements, appointment of directors, ratification of auditor remuneration, approval of related party transactions, and revisions in remuneration of executive directors. The document is a formal notice and includes the Annual Report as an enclosure, but the text itself is primarily the notice and agenda for the AGM, not the full Annual Report. The document length is 15,000 characters, which is substantial, but the text is clearly a Notice of AGM and Annual Report availability rather than the full Annual Report itself. According to the "Menu vs Meal" rule, if a document states that the Annual Report is submitted or attached but does not contain the full report's financial statements and detailed disclosures, it should be classified as AGM Information (AGM-R). Therefore, this document is best classified as AGM Information (AGM-R).
2025-07-16 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release submitted under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, announcing a strategic realignment of Wockhardt's US operations, including voluntary liquidation of subsidiaries. It contains no detailed financial statements or comprehensive financial analysis but rather an update on corporate strategy and operational changes. The document length is 7,588 characters, which is relatively short and consistent with an announcement rather than a full report. It explicitly states it is a press release and includes an annexure with regulatory disclosure details as required by SEBI. There is no indication of it being a full annual or interim report, audit report, earnings release, or other detailed financial document. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and disclosures that do not fit other specific categories.
2025-07-11 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short official notice from the company informing the stock exchanges about the closure of the trading window in compliance with the company's Code of Conduct. It mentions the upcoming unaudited financial results for the quarter ended June 30, 2025, but does not contain any financial data or results itself. The document is only an announcement related to trading restrictions ahead of financial results disclosure. Given its brevity (1208 characters) and nature as a notification, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a financial report or earnings release.
2025-06-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a detailed transcript of an investor conference held by Wockhardt Limited on June 5, 2025. It includes a comprehensive presentation by the Managing Director covering company performance, financial results, product pipeline updates, clinical trial progress, and strategic outlook. The text contains detailed financial figures, operational highlights, and future plans, typical of an investor presentation. The document also mentions a Q&A session and is explicitly titled as an "Investor Conference" transcript. There is no indication that this is a brief announcement or a regulatory filing; rather, it is a full transcript of a conference call/presentation. Therefore, the document fits the definition of a Call Transcript (CT).
2025-06-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.